- Home
- CLDX vs IMNM Comparison
CLDX vs IMNM Comparison
Compare CLDX & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLDX | IMNM |
|---|---|---|
| Founded | N/A | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.6B |
| IPO Year | 1995 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CLDX | IMNM |
|---|---|---|
| Price | $35.57 | $22.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 10 |
| Target Price | ★ $46.60 | $32.80 |
| AVG Volume (30 Days) | 1.3M | ★ 1.7M |
| Earning Date | 05-04-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 51.40 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,743,000.00 | $6,941,000.00 |
| Revenue This Year | $111.39 | N/A |
| Revenue Next Year | $235.85 | $1,127.34 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 87.78 | N/A |
| 52 Week Low | $19.72 | $8.67 |
| 52 Week High | $40.30 | $27.65 |
Technical Indicators
Market Signals| Indicator | CLDX | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 49.03 | 54.20 |
| Support Level | $28.51 | $19.28 |
| Resistance Level | $40.30 | $23.25 |
| Average True Range (ATR) | 1.76 | 1.36 |
| MACD | -0.38 | -0.01 |
| Stochastic Oscillator | 20.07 | 49.81 |
Price Performance
Historical ComparisonAbout CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
About IMNM Immunome Inc.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.